stockrow
Friday 6 November 2026
Export MMED’s income statement to Excel — free account
MiniMed Group, Inc.
MMED Healthcare Medical Instruments & Supplies
MiniMed Group, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $3.1 billion, up 14.3% from fiscal 2025.
17.07
1.09
−6.00%
Follow MMED
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to April
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM Jul ’26 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 2,469 | 2,715 | 3,102 | 3,043 | +12.1% | 3,436 | 3,728 | 4,101 | +9.8% | |
| Gross margin, % | — | — | — | — | — | — | — | 58.20 | 56.28 | 54.16 | 53.60 | (4.0) pt | ||||||
| EBT | — | — | — | — | — | — | — | (70) | (147) | (189) | (87) | +64.3% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | (2.84) | (5.41) | (6.09) | (2.86) | (3.2) pt | ||||||
| Net income | — | — | — | — | — | — | — | (107) | (198) | (317) | (320) | +72.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 9.77 | 10.74 | 12.09 | 10.83 | +11.3% | |||||
| Earnings | — | — | — | — | — | — | — | (0.42) | (0.84) | (1.29) | (0.59) | +74.6% | ||||||
| Cash flow | — | — | — | — | — | — | — | 0.16 | 0.55 | (0.77) | (0.48) | n/m | ||||||
| Capex | — | — | — | — | — | — | — | (0.59) | (0.76) | (0.87) | (1.13) | +21.8% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (0.42) | (0.21) | (1.64) | (1.61) | +96.6% | ||||||
| Book value | — | — | — | — | — | — | — | 0.00 | 13.17 | 14.07 | 12.88 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 253 | 253 | 257 | 260 | +0.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 1.68 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | — | 1.35 | 1.35 | 0.86 | 1.42 | 1.2 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 1.62 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (10.58) | (10.58) | (6.40) | (10.88) | (9.2) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | 41 | 140 | (197) | (134) | n/m | |||||
| Capex | — | — | — | — | — | — | — | (148) | (193) | (223) | (318) | +22.8% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (107) | (53) | (420) | (452) | +98.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 229 | 646 | 635 | +182.1% | |||||
| Net debt | — | — | — | — | — | — | — | — | (11) | (298) | (207) | +2,609.1% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 3,330 | 3,611 | 3,620 | +8.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (10.14) | (7.54) | (6.27) | (7.5) pt | |||||
| ROIC | — | — | — | — | — | — | — | 0.00 | (2.73) | (3.58) | (1.61) | (3.6) pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | 0.00 | (9.59) | 0.00 | (9.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 3,000 | 2,800 | — | (6.7%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.91 | 1.11 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Apr 2026 · latest quarter Jul 2026 · fundamentals updated 26 Oct 2026
MiniMed Group, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BLCO Bausch + Lomb Corporation | $7.1B | — (loss-making) | 749× | +7.34% (above 0%: growing) | n/m | +182.54% (above 0%: growing) | 64.65% | 11.27% | Compare |
| TFX Teleflex Incorporated | $6.5B | — (loss-making) | 37.4× | +28.88% (above 0%: growing) | −17.33% (below 0%: shrinking) | +220.14% (above 0%: growing) | 58.16% | 12.77% | Compare |
| MMSI Merit Medical Systems, Inc. | $5.4B | 33.2× | 30.7× | +8.35% (above 0%: growing) | +50.53% (above 0%: growing) | +50.18% (above 0%: growing) | 48.20% | 14.12% | Compare |
| MMED MiniMed Group, Inc. | $5.1B | — (loss-making) | 27.8× | — | n/m | −13.92% (below 0%: shrinking) | 55.16% | 0.47% | |
| ICUI ICU Medical, Inc. | $4.2B | 69.3× | 48.8× | +4.37% (above 0%: growing) | n/m | +292.20% (above 0%: growing) | 41.89% | 9.34% | Compare |
| NVST Envista Holdings Corporation | $4.0B | 6.4× | 21.5× | +3.22% (above 0%: growing) | n/m | −6.48% (below 0%: shrinking) | 57.93% | 74.50% | Compare |
| PLSE Pulse Biosciences, Inc | $3.9B | — (loss-making) | — (loss-making) | +359.30% (above 0%: growing) | n/m | −1,180.54% (below 0%: shrinking) | 51.65% | (6,149.87%) | Compare |
| STVN Stevanato Group S.p.A. | $3.6B | 22.4× | 30.2× | +5.91% (above 0%: growing) | +17.53% (above 0%: growing) | +4,089.92% (above 0%: growing) | 29.12% | 18.51% | Compare |
| ATRC AtriCure, Inc. | $3.1B | 199× | 573× | +15.03% (above 0%: growing) | n/m | −0.73% (below 0%: shrinking) | 77.27% | 2.82% | Compare |
| Median of peers | $4.1B | 33.2× | 37.4× | +7.85% | +17.53% | +116.36% | 54.79% | 12.02% |
Pay and ownership Proxy statement filed 21 August 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2026 | 8.43m | 4.38m | 71.39 |
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Read the proxy statement
MiniMed Group, Inc. (MMED) Latest News
15 Oct
14 Sep
1 Sep
20 Aug
MMED metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share